
About
With founders who are global leaders in the structural biology of 14-3-3 proteins and their role in a wide range of protein-protein interactions, our team is developing a new class of medicines that can modulate previously undruggable targets and influence currently accessible ones in new ways. These small molecule stabilizers of 14-3-3:client complexes have the potential to address serious unmet needs in important therapeutic areas including cancer, metabolic disorders, neurodegenerative and infectious diseases.
Our company is committed to aggressively expanding the boundaries of medicine through treatments that modulate some of the most challenging and potentially impactful targets identified across the proteome, with the goal of treating diseases that currently lack a cure and helping patients live longer and healthier lives.

Donna Debets, Ph.D.
Senior Scientist, Proteomics

Laura Demmers, Ph.D.
Senior Scientist, Proteomics

Tanja Meyer Ph.D.
VP & Head of Corporate Strategy & Business Development

Ceri Zwart
Associate Scientist, Proteomics

Tom van de Wijngaart
Associate Scientist, Structural Biology

Shannon Vogelaar
Senior Research Associate, Proteomics
Investors



